Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241210379 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Florian Rissel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Saint Eloi, Montpellier University Hospital, Montpellier University, 34295 Montpellier, France. Hauptthemen laut MEDLINE: Drug Monitoring, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Therapeutic drug monitoring (TDM) of anti-TNF-α is an important tool in clinical practice for inflammatory diseases. In this study, we have evaluated the performance of several assays for drug and antidrug antibodies (ADA) measurement in the serum. 50 sera from patients treated with infliximab (IFX) and 49 sera from patients treated with adalimumab (ADAL) were monitored with four immunoassays. We have compared Promonitor, i-Track10®, and ez-track1 assays to our gold standard Lisa Tracker® ELISA using Cohen’s kappa, Passing-Bablok, and Bland–Altman analysis. The qualitative analysis evaluated by Cohen’s kappa values found for IFX measurements an “almost perfect” concordance for Promonitor, “moderate” for i-Track10® and “substantial” for ez-Track1. For ADAL, kappa values were “moderate” for all tested methods. For anti-IFX, kappa values were “almost perfect” for Promonitor, “fair” for i-Track10®, and “substantial” for ez-Track1. For anti-ADAL, kappa values were “almost perfect” for all three assays. For quantitative analysis of drug measurements, Pearson’s r values were all above 0.9 and Lin’s concordance coefficients of all immunoassays were around 0.80. Performances of the four evaluated immunoassays were acceptable for TDM based on our laboratory experience. Nevertheless, concordance between the four methods for IFX measurement was not perfect and we recommend the use of the same assay for the follow-up of a given patient. The performances of the four immunoassays evaluated were similar and are acceptable for TDM based on our laboratory experience.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Saint Eloi, Montpellier University Hospital, Montpellier University, 34295 Montpellier, France.
- Institute Desbrest of Epidemiology and Public Health, Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Pharmacology and Toxicology, Montpellier University Hospital, Montpellier Universit…
- Department of Hepato-Gastroenterology, Saint Eloi, Montpellier University Hospital, Montpellier University, 34295 Montpellier, France.
ORCID-Profile: Yoann Cazaubon
Zitieren
APA
Rissel, F., Cazaubon, Y., Saffar, S., Altwegg, R., Artasone, M., Lozano, C., Vincent, T., & Jentzer, A. (2023). Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241210379
Vancouver
Rissel F, Cazaubon Y, Saffar S, Altwegg R, Artasone M, Lozano C, et al. Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241210379
BibTeX
@article{Rissel2023,
author = {Rissel, Florian and Cazaubon, Yoann and Saffar, Syrine and Altwegg, Romain and Artasone, Mélanie and Lozano, Claire and Vincent, Thierry and Jentzer, Alexandre},
title = {Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241210379}
}
EUVIMED